- Conditions
- Healthy, no Evidence of Disease
- Interventions
- Bowman-Birk inhibitor concentrate, placebo, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 1,765
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dengue
- Interventions
- Placebo (SC), Placebo (ID), Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- Placebo (blinded), LX9211 (blinded)
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 108
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 91 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Placebo, 100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Maitland, Florida
- Conditions
- Hallux Valgus and Bunion
- Interventions
- Analgesic Non Narcotic
- Drug
- Lead sponsor
- Cali Pharmaceuticals LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Bakersfield, California • Salt Lake City, Utah
- Conditions
- Alzheimer Disease
- Interventions
- Mediterranean Diet, Study Supplement, Low-fat Diet
- Behavioral · Dietary Supplement
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Streptococcus Pneumoniae
- Interventions
- PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 84 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more
- Conditions
- Migraine
- Interventions
- Lu AG09222, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthspan Improvement, Aging, Longevity
- Interventions
- Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
- Drug · Dietary Supplement · Behavioral
- Lead sponsor
- AgelessRx
- Industry
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Schizophrenia
- Interventions
- Low Dose Asenapine maleate transdermal patch, High Dose Asenapine maleate transdermal patch, Placebo
- Drug
- Lead sponsor
- Noven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Jersey City, New Jersey
- Conditions
- Diabetes type1
- Interventions
- AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose
- Biological · Drug
- Lead sponsor
- Precigen Actobio T1D, LLC
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
- Interventions
- LFMS
- Device
- Lead sponsor
- Tal Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 12
- States / cities
- Garden Grove, California • Lemon Grove, California • Oakland, California + 9 more
- Conditions
- Alzheimer Disease
- Interventions
- Interleukin-2, Placebo
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 50 Years to 86 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C)
- Interventions
- SYN-010 21 mg, SYN-010 42 mg, Placebo
- Drug
- Lead sponsor
- Theriva Biologics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Placebo, Foradil
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 13
- States / cities
- Jasper, Alabama • Clearwater, Florida • DeLand, Florida + 10 more
- Conditions
- Clostridium Difficile Associated Disease
- Interventions
- Clostridium difficile vaccine, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 12
- States / cities
- DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more
- Conditions
- Ureter Injury
- Interventions
- 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%, Saline spray
- Drug
- Lead sponsor
- Prove pharm
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety Disorders
- Interventions
- Low-Dose Cannabidiol, Placebo Matched to Moderate-Dose Cannabidiol, Moderate-Dose Cannabidiol, Placebo Matched to Low-Dose Cannabidiol
- Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Non Celiac Gluten Sensitivity
- Interventions
- High dose Gluten, Low dose Gluten, Lactose free placebo
- Dietary Supplement
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Low-back Pain, Degenerative Disc Disease
- Interventions
- CELZ-201-DDT, Placebo
- Drug · Other
- Lead sponsor
- Creative Medical Technology Holdings Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Aventura, Florida
- Conditions
- Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
- Interventions
- Evolocumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
- Conditions
- Infantile Spasms, Infantile Epileptic Spasms Syndrome, West Syndrome
- Interventions
- Prednisolone, Famotidine, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 2 Months to 18 Months
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alcohol Drinking, Ethanol Intoxication, Breastfeeding
- Interventions
- Low-alcohol level exposure, Breast-pumping time
- Other
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 21 Years to 45 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- HIV Infections
- Interventions
- Interferon alfa-n3, Interferon alfa-n1
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2002
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Redwood City, California • New Haven, Connecticut + 9 more